Durable deep molecular response via CD19 chimeric antigen receptor T-cell therapy combined with a third-generation tyrosine kinase inhibitor in acute leukemia of ambiguous lineage with the Philadelphia chromosome: a potential strategy for transplant-ineligible patients
This research aims to explore the effectiveness of combining CD19 CAR T-cell therapy with a third-generation tyrosine kinase inhibitor in treating acute leukemia.
Examined the use of CD19 chimeric antigen receptor T-cell therapy.
Incorporated a third-generation tyrosine kinase inhibitor in the treatment plan.
Focused on patients with acute leukemia and the Philadelphia chromosome.
Targeted transplant-ineligible populations.
Demonstrated a durable deep molecular response in the targeted patient group.
Showed improvements in treatment outcomes compared to traditional options.
Highlighted the potential for increased survival rates in patients.